First-line therapy for an acute gout flare is which NSAID?

Prepare for the NBME Form 10 Step 2 Test. Utilize flashcards and multiple choice questions, with hints and explanations for each. Ace your exam preparation!

Multiple Choice

First-line therapy for an acute gout flare is which NSAID?

Explanation:
An acute gout flare is driven by intense inflammation from urate crystals, so the first priority is rapidly suppressing that inflammatory response with a potent NSAID. Indomethacin is the classic first-line choice because it provides strong anti-inflammatory effects and fast relief of joint swelling and pain. It works by broadly inhibiting prostaglandin synthesis in inflamed tissues, which directly dampens the neutrophil-driven inflammatory cascade seen in gout. While other NSAIDs like naproxen can be effective, indomethacin has the strongest historical support for acute gout management. Acetaminophen lacks anti-inflammatory action and is not sufficient to treat the inflammatory component. Celecoxib, a COX-2 inhibitor, can be used in patients with GI risk but is not the traditional first-line in this scenario due to differing efficacy data and considerations.

An acute gout flare is driven by intense inflammation from urate crystals, so the first priority is rapidly suppressing that inflammatory response with a potent NSAID. Indomethacin is the classic first-line choice because it provides strong anti-inflammatory effects and fast relief of joint swelling and pain. It works by broadly inhibiting prostaglandin synthesis in inflamed tissues, which directly dampens the neutrophil-driven inflammatory cascade seen in gout. While other NSAIDs like naproxen can be effective, indomethacin has the strongest historical support for acute gout management. Acetaminophen lacks anti-inflammatory action and is not sufficient to treat the inflammatory component. Celecoxib, a COX-2 inhibitor, can be used in patients with GI risk but is not the traditional first-line in this scenario due to differing efficacy data and considerations.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy